What is the lead time for peak seasons?

The average lead time during peak seasons is one month.

What payment terms are accepted?

Accepted payment terms include LC and T/T.

Is the solution suitable for elderly patients?

Yes, the solution is suitable for both elderly and adult patients.

Peritoneal Dialysis Solution (Lactate-G1.5%, G2.5%, G4.25%)

Name: Peritoneal Dialysis Solution (Lactate-G1.5%, G2.5%, G4.25%)
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 2077009135

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$2.00

20,000 BOTTLE

Sample price:US$2.00/bottle.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

Internal Use

Model NO.

Suitable for

Elderly, Adult

State

Liquid

Shape

Liquid

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Production Line

ISO GMP

Transport Package

Carton

Specification

Trademark

SHIMEN

Origin

China

HS Code

3004909099

Production Capacity

1000000

Key features

Clear Solution Appearance: Colorless to pale yellow clear solution for medical use.

Multiple Glucose Concentrations: Available in Lactate-G1.5%, G2.5%, and G4.25% variants.

Non-PVC Packaging: 2L Non-PVC plastic bag, 6 bags per carton.

GMP Compliant Production: Manufactured on ISO GMP certified fully automated production lines.

Renal Failure Treatment: Indicated for acute or chronic renal failure and electrolyte disorders.

Global Export Reach: Exported to over 80 countries across Asia, Americas, Europe, and Africa.

70-Year Brand History: Leading manufacturer with seventy years of pharmaceutical industry experience.

Advanced R&D Capability: Powerful R&D team with major scientific innovation achievements.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤24hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.